Top Page
Shandong Weigao Group Medical Polymer Co
(OTC:1066)
Shandong Weigao Group Medical Polymer Co (1066) vs. iShares MSCI Hong Kong ETF (EWH)
Shandong Weigao Group Medical Polymer Co Business Overview & Revenue Model
Shandong Weigao Group Medical Polymer Co Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 13.09B | 13.23B | 13.62B | 13.15B | 11.35B | Gross Profit |
| 6.58B | 6.64B | 7.11B | 7.27B | 6.46B | EBIT |
| 2.39B | 2.18B | 3.56B | 3.32B | 2.61B | EBITDA |
| 3.14B | 3.55B | 4.38B | 3.75B | 3.30B | Net Income Common Stockholders |
| 2.07B | 2.00B | 2.76B | 2.28B | 2.09B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 8.32B | 7.33B | 7.36B | 7.06B | 5.98B | Total Assets |
| 34.76B | 33.67B | 33.20B | 30.37B | 27.34B | Total Debt |
| 4.19B | 4.17B | 4.49B | 4.14B | 4.32B | Net Debt |
| -3.59B | -2.82B | -2.37B | -2.49B | -1.19B | Total Liabilities |
| 9.42B | 9.68B | 9.75B | 9.46B | 8.95B | Stockholders Equity |
| 23.75B | 22.45B | 21.67B | 19.27B | 17.55B |
| Cash Flow | Free Cash Flow | |||
| 2.14B | 2.11B | 1.10B | 1.92B | 1.70B | Operating Cash Flow |
| 2.79B | 2.80B | 2.21B | 3.04B | 2.70B | Investing Cash Flow |
| -1.10B | -1.39B | -2.57B | -1.48B | 423.22M | Financing Cash Flow |
| -1.60B | -2.16B | -1.02B | -538.08M | -1.79B |
Shandong Weigao Group Medical Polymer Co Technical Analysis
Shandong Weigao Group Medical Polymer Co Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | €9.37B | 14.42 | 18.36% | 3.78% | 7.13% | 13.39% | |
81 Outperform | €1.59B | 9.82 | 3.72% | 9.09% | 11.84% | -2.22% | |
77 Outperform | $27.90B | 12.27 | 8.95% | 4.36% | -3.09% | 0.67% | |
74 Outperform | €3.97B | 9.80 | 15.04% | 4.35% | 6.05% | 1.32% | |
68 Neutral | HK$17.06B | 31.91 | 28.81% | 1.49% | 14.99% | 31.70% | |
66 Neutral | HK$4.51B | 20.16 | 11.24% | 1.18% | 11.23% | 20.39% | |
54 Neutral | $5.41B | 3.27 | -45.10% | 3.29% | 16.81% | 0.02% |
Shandong Weigao Group Medical Polymer Co Corporate Events
Shandong Weigao Group Medical Polymer Company Limited announced a change in its board leadership effective 28 May 2025. Mr. Tang Zhengpeng has resigned as Vice-Chairman but will continue his role as a non-executive Director and committee member. Ms. Yan Xia, previously a non-executive Director, will succeed him as Vice-Chairman. This leadership transition is part of the company’s strategic reassignment of duties and responsibilities, potentially impacting its governance and stakeholder relations.
The most recent analyst rating on (HK:1066) stock is a Buy with a HK$6.40 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.
Shandong Weigao Group Medical Polymer Company Limited has announced the composition of its board of directors and their respective roles. This announcement provides clarity on the governance structure of the company, potentially impacting its strategic direction and operational oversight, which is crucial for stakeholders and investors.
The most recent analyst rating on (HK:1066) stock is a Buy with a HK$6.40 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.
Shandong Weigao Group Medical Polymer Co. has announced a final cash dividend of RMB 0.1235 per share for the financial year ending December 31, 2024, with shareholder approval scheduled for May 27, 2025. The dividend will be paid in Hong Kong dollars at an exchange rate of RMB 1 to HKD 1.0888, with a payment date set for July 11, 2025. The announcement also details the withholding tax rates applicable to non-resident shareholders, with a 10% rate for enterprises and individuals outside China and a 20% rate for domestic individual investors using the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect.
The most recent analyst rating on (HK:1066) stock is a Buy with a HK$6.40 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.
Shandong Weigao Group Medical Polymer Company Limited held its Annual General Meeting on 27 May 2025, where all proposed resolutions were successfully passed by poll. Key resolutions included the approval of the audited financial statements for 2024, the declaration of a final dividend, and the reappointment of Deloitte Touche Tohmatsu as the company’s auditor. The successful passing of these resolutions indicates strong shareholder support and positions the company for continued stability and growth.
The most recent analyst rating on (HK:1066) stock is a Buy with a HK$6.40 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.
Shandong Weigao Group Medical Polymer Company Limited has made an overseas regulatory announcement in compliance with the disclosure requirements of the Hong Kong Stock Exchange. The announcement, which was also published on the Shanghai Stock Exchange’s website, highlights the company’s adherence to regulatory standards, potentially impacting its market positioning and stakeholder confidence positively.
Shandong Weigao Group Medical Polymer Company Limited has announced its upcoming annual general meeting (AGM) scheduled for May 27, 2025. The AGM will address various resolutions, including the approval of the company’s audited financial statements for 2024, the declaration of a final dividend, re-appointment of auditors, and re-election of directors and supervisors. Additionally, a special resolution will consider granting the board a general mandate to issue and deal with shares. These resolutions are crucial for the company’s governance and strategic planning, potentially impacting its market positioning and shareholder value.
Shandong Weigao Group Medical Polymer Company Limited has made an overseas regulatory announcement in compliance with the disclosure requirements of the Hong Kong Stock Exchange. This announcement, published on the Shanghai Stock Exchange website, signifies the company’s adherence to regulatory standards and may impact its market positioning by enhancing transparency and investor confidence.
Shandong Weigao Group Medical Polymer Company Limited has made an overseas regulatory announcement in compliance with the disclosure requirements of the Hong Kong Stock Exchange. This announcement, published on the Shanghai Stock Exchange website, is part of the company’s ongoing regulatory obligations, reflecting its commitment to transparency and adherence to market regulations.
Shandong Weigao Group Medical Polymer Company Limited has made an overseas regulatory announcement in compliance with the disclosure requirements of the Hong Kong Stock Exchange. The announcement was also published on the Shanghai Stock Exchange’s website, indicating the company’s adherence to regulatory standards and its commitment to transparency in its operations.
Shandong Weigao Group Medical Polymer Co has announced a final cash dividend of RMB 0.1235 per share for the financial year ending December 31, 2024. This announcement reflects the company’s financial health and commitment to returning value to its shareholders, potentially impacting its market positioning positively.
Shandong Weigao Group Medical Polymer Company Limited reported a slight decrease in revenue for the year ended December 31, 2024, with a total of approximately RMB13.09 billion, down 1.1% from the previous year. However, the company achieved a 3.2% increase in net profit attributable to its owners, reaching approximately RMB2.07 billion. The directors have recommended a final dividend of RMB0.1235 per share, pending shareholder approval. This financial performance highlights the company’s resilience and potential for growth despite a challenging market environment.